Acetylleucine is under clinical development by IntraBio and currently in Phase II for Spinocerebellar Ataxia (SCA). According to GlobalData, Phase II drugs for Spinocerebellar Ataxia (SCA) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Acetylleucine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acetylleucine overview
Acetylleucine (IB-1001) is under development for the treatment of Niemann-Pick disease type C, GM1 Gangliosidosis, GM2 gangliosidosis, ataxia telangiectasia, spinocerebellar ataxia, Tay-Sachs Disease, multiple systems atrophy and Sandhoff disease. It is administered orally as powder for suspension.
It was under development for Lewy body dementia and frontotemporal dementia, Niemann-Pick disease type A and B and Alzheimer's Disease.
IntraBio overview
IntraBio is a private pharmaceutical company that focuses on the development and commercialization of novel and repurposed drugs to treat common and rare neurodegenerative diseases, including lysosomal storage disorders. The company is headquartered in Oxford, Oxfordshire, the UK.
For a complete picture of Acetylleucine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.